The FDA announced Tandem Diabetes recalled the t:connect mobile app, an Apple iOS-based software for Version 2.7 of the mobile app. The t:connect mobile app works with the t:slim X2 insulin pump with Control-IQ technology. The reason for the recall is due to an issue with the software that may cause the mobile app to crash and be automatically relaunched by the iOS operating system, the agency said. This cycle intermittently repeats, which leads to excessive Bluetooth communication that may result in pump battery drain and may lead to the pump shutting down sooner than typically expected, it added. There have been 224 reported injuries as of April 15 and no reports of death.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $55 from $39 at Barclays
- Tandem Diabetes price target raised to $50 from $35 at Piper Sandler
- Tandem Diabetes price target raised to $50 from $45 at Wells Fargo
- Tandem Diabetes price target raised to $45 from $35 at TD Cowen
- Tandem Diabetes price target raised to $36 from $28 at Baird